Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
Business Of Biotech
00:00
The Business of Biotech Podcast - Backslash Emerging Biotech
This wasn't an indication that was necessarily on our radar from the get-go, but what the team did really well is actually follow the science. The science guided them towards the neutrophilic diseases, neutrophilic dermatosis. They saw a clear pattern, a clear biology there. That's C-Y-T-I-V-A. Check out their resources at siteiva.com backslash emerging biotech.
Transcript
Play full episode
